zinc-finger protein transcription factors

[Sangamo Therapeutics] Sangamo Therapeutics, Inc. announced that it has executed a global licensing collaboration agreement with Novartis to develop and commercialize gene regulation therapies to address three neurodevelopmental targets, including autism spectrum disorder and other neurodevelopmental disorders.